The next generation of ADCs included brentuximab vedotin, used to treat Hodgkin’s lymphoma and anaplastic large-cell lymphoma, and trastuzumab emtansine, used for HER2-positive breast cancer treatment (Nagayama et al. 2020). This evidence concerns the gene ERBB2 and breast cancer.